tiprankstipranks
Trending News
More News >

Shandong Xinhua Pharmaceutical Gains Approval for Ibuprofen Arginine

Story Highlights
Shandong Xinhua Pharmaceutical Gains Approval for Ibuprofen Arginine

Don’t Miss TipRanks’ Half-Year Sale

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an announcement.

Shandong Xinhua Pharmaceutical Company Limited announced that it has received approval from the National Medical Products Administration for the marketing application of its product, Ibuprofen Arginine. This approval allows the company to register the product, which is used for treating various types of pain and fever, and is part of the Class B variety in China’s National Drug Catalogue. The approval is expected to enhance the company’s market presence and potentially increase its sales in China’s public medical institutions.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and marketing of chemical substance drugs. The company is involved in the pharmaceutical industry, with a market focus on domestic production of chemical raw materials.

Average Trading Volume: 4,889,496

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.26B

See more insights into 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1